Characteristics of the randomized controlled trials for efavirenz compared to different regimens used to treat antiretroviral–naive HIV-infected adult patients.

3TC—lamivudine, ABC—abacavir, APL—aplaviroc, APV—amprenavir, ART—antiretroviral therapy, ATV—atazanavir, AZT—zidovudine, bid—twice a day, bPI—ritonavir-boosted protease inhibitor, CCR5—CC chemokine receptor type 5, COBI—cobicistat, d4T - stavudine, ddC—zalcitabine, ddI—didanosine, DTG—dolutegravir, EFV—efavirenz, ETV—etravirine, EVG—elvitegravir, FPV—fosamprenavir, FTC—emtricitabine, IDV—indinavir, MVC—maraviroc, LPV—lopinavir, LRV—lersivirine, NFV—nelfinavir, NNRTI—non-nucleoside reverse transcriptase inhibitor, NRTI—nucleoside reverse transcriptase inhibitor, NVP—nevirapine, PI—protease inhibitor, r—ritonavir, RAL—raltegravir, RCT—randomized controlled trial, RPV—rilpivirine, SQV—saquinavir, TDF—tenofovir, pVL—plasma HIV RNA, VCV—vicriviroc.* interventions included in meta-analysis only.**raltegravir monotherapy did not influenced the efficacy results, so both groups (pretreated and not pretreated with raltegravir were combined).***results for groups assigned EFV + different NRTIs and separately ATV/r + different NRTIs were combined.#enrolment in the TDF + ddI + EFV arm was stopped as soon as the high rate of virological failure was recognized.##once-daily MVC arm was discontinued prematurely and not analyzed.###stopped prematurely due to unexpected hepatotoxicity.Characteristics of the randomized controlled trials for efavirenz compared to different regimens used to treat antiretroviral–naive HIV-infected adult patients.